As part of BioBuzz’s Off the Record event —held in partnership with EMINENT Life Sciences—the inaugural gathering took place at the EMINENT Life Sciences Campus in Frederick, Maryland,a dynamic hub that houses both CIAN Diagnostics and EMINENT Life Sciences itself.
The evening opened with a very compelling fireside chat titled “The Next Frontier: Cell & Gene Therapy”, which spotlighted the evolving role of cell and gene therapies as they move from niche applications to more widespread clinical use.
Featuring Dr. Patrick Hanley, Chief & Director of the Cellular Therapy Program at Children’s National Hospital, and Dr. Emily English, COO, Cartesian Therapeutics, the conversation offered a rare look at how both academic and commercial leaders are addressing scalability, patient access, and regulatory alignment in one of biotech’s most promising fields.
Key Highlights
Cell & Gene Therapy Is Stepping into the Mainstream
What began as a last-resort treatment for rare cancers is rapidly becoming a platform technology for autoimmune diseases and beyond. Dr. Emily English highlighted Cartesian Therapeutics’ lead candidate, Descartes-08, which is now in Phase 3 trials for myasthenia gravis. If successful, it could mark the first placebo-controlled trial of an autologous cell therapy for this condition.
“That’s why I’m excited,” added Dr. Hanley. “It’s becoming mainstream.”
A Widening Spectrum: Academic vs. Commercial Models
The conversation also explored the spectrum between academic and commercial development pathways. Dr. Hanley noted that Children’s National has manufactured more than 600 Investigational New Drug (IND) products across 25 clinical trials—an extraordinary academic footprint. Meanwhile, Cartesian is navigating the path to late-stage commercialization by scaling its manufacturing operations in-house and preparing for regulatory and clinical supply chains. Together, their dialogue highlighted how different institutional models are critical to advancing the field.
Rethinking Manufacturing for Scalability
As the complexity and cost of cell therapies continue to challenge developers, both panelists emphasized the need for innovative delivery approaches. Ideas such as decentralized GMP facilities or “kit-based” cell therapies could one day bring production closer to the point of care—making these treatments more accessible to patients in underserved regions.
The FDA: Partner, Not Obstacle
Dispelling a common myth, both Dr. Hanley and Dr. English spoke to their positive experiences working with regulators.
“People think the FDA and industry are adversarial… that has not been my experience at all,” said Dr. Hanley.
Dr. English agreed, emphasizing that clearer regulatory frameworks often help—not hinder—innovation by establishing predictable pathways for new entrants.
Infrastructure Is Finally Catching Up to the Science
Despite the promise of CAR-T therapy, access remains a barrier.
“Only about 20% of eligible patients currently receive CAR-T therapy,” said Dr. Hanley, calling for major improvements in delivery and logistics.
He expressed optimism that emerging courier systems, advanced patient-matching protocols, and a growing network of qualified treatment centers could significantly expand access in the coming years.
The Mid-Atlantic Advantage
In closing, Dr. Hanley emphasized the region’s unique positioning near key federal agencies like the FDA, NIH, and NSF, calling it a strategic advantage for innovators.
“We’re in a very unique place… There’s a lot of investment and promise here,” he said, encouraging attendees to engage with the CHARM network and stay connected to the local ecosystem.
This Message resonated deeply with many in attendance, including Jake Jakubek, who shared:
“Attending this event made me realize just how many brilliant people are in Maryland, each working on fascinating ideas and pushing them toward real-world impact.”
His sentimnet echoed a common takeaway: That beyound technical insight, events like these offer a renewed appreciation of the region’s talent, collaboration, and momentum.
